Epigenetic reprogramming of Runx3 reinforces CD8 + T-cell function and improves the clinical response to immunotherapy

BACKGROUND: Checkpoint blockade immunotherapy, represented by PD-1 or PD-L1 antibody treatment, has been of tremendous success in clinical practice. However, the low clinical response rate and lack of biomarkers for prediction of the immune response limit the clinical application of anti-PD-1 immuno...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zongzhi, Li, Xiang, Gao, Yibo, Liu, Jiejie, Feng, Yating, Liu, Yang, Wang, Junyun, Wang, Chunmeng, Wang, Dongrui, He, Jie, Han, Weidong, Mei, Qian, Sun, Yingli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186650/
https://www.ncbi.nlm.nih.gov/pubmed/37189103
http://dx.doi.org/10.1186/s12943-023-01768-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186650/
https://www.ncbi.nlm.nih.gov/pubmed/37189103
http://dx.doi.org/10.1186/s12943-023-01768-0

Ejemplares similares